Literature DB >> 23592134

Association of preoperative serum IGF- I concentration with clinicopathological parameters in patients with non-small cell lung cancer.

Sheng-Ling Fu1, He-Xiao Tang1, Yong-de Liao2, Wen-Yang Jiang1, Qin-Zi Xu1, Yu Deng1, Xiang-Ning Fu1.   

Abstract

Insulin-like growth factor-I (IGF-I) is a mitogenic and anti-apoptotic factor. Serum IGF-I concentration is related to some cancer risk and tumor progression. The aim of this research was to study the association of preoperative serum IGF-I concentration with clinicopathological parameters and prognosis of non-small cell lung cancer (NSCLC). Preoperative serum IGF-I concentration was measured in 80 consecutive patients with NSCLC who underwent radical lung cancer resection, and 45 patients with benign pulmonary lesion (BPL) by using enzyme linked immunosorbent assay (ELISA). The results showed that the serum IGF-I concentration was elevated and correlated with clinicopathological parameters and overall survival (OS) in NSCLC patients. Serum IGF-I concentration was significantly higher in patients with NSCLC than in those with BPL. The IGF-I concentrations were significantly higher in NSCLC patients with ≥T2, N1-3, and in IIIA-IV but not in those with <T2, N0, or IA-IIB. The increased serum IGF-I concentration was significantly correlated with poor prognosis. Our data show the positive correlation between IGF-I serum concentration and the tumor size for the first time. It seems that IGF-I related to the progression of lung cancer may depend on autocrine/paracrine function. In addition, our study reveals that higher serum IGF-I concentration is correlated with larger tumor size, advanced stages, local lymph node metastasis and worse prognosis, indicating that endocrine IGF-I is also important for the progression for NSCLC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23592134     DOI: 10.1007/s11596-013-1101-3

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  13 in total

1.  Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells.

Authors:  Kyung-Hee Chun; Jerome W Kosmeder; Shihua Sun; John M Pezzuto; Reuben Lotan; Waun Ki Hong; Ho-Young Lee
Journal:  J Natl Cancer Inst       Date:  2003-02-19       Impact factor: 13.506

2.  Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer.

Authors:  David D Shersher; Michael S Vercillo; Cristina Fhied; Sanjib Basu; Omid Rouhi; Brett Mahon; John S Coon; William H Warren; L Penfield Faber; Edward Hong; Philip Bonomi; Michael J Liptay; Jeffrey A Borgia
Journal:  Ann Thorac Surg       Date:  2011-09-25       Impact factor: 4.330

3.  Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients.

Authors:  P J Vlachostergios; I Gioulbasanis; K Kamposioras; P Georgoulias; V E Baracos; S Ghosh; E Maragouli; V Georgoulias; C N Papandreou
Journal:  Oncology       Date:  2011-10-04       Impact factor: 2.935

Review 4.  Clinical development of inhibitors of the insulin-like growth factor receptor in oncology.

Authors:  Antonio Gualberto; Michael Pollak
Journal:  Curr Drug Targets       Date:  2009-10       Impact factor: 3.465

5.  Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells.

Authors:  Götz von Wichert; Ulla Haeussler; Florian R Greten; Stefanie Kliche; Henning Dralle; Bernhard O Böhm; Guido Adler; Thomas Seufferlein
Journal:  Oncogene       Date:  2005-02-10       Impact factor: 9.867

Review 6.  Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis.

Authors:  A Grimberg; P Cohen
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

7.  The role of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in human esophageal cancer.

Authors:  Makoto Sohda; Hiroyuki Kato; Tatsuya Miyazaki; Masanobu Nakajima; Minoru Fukuchi; Ryokuhei Manda; Yasuyuki Fukai; Norihiro Masuda; Hiroyuki Kuwano
Journal:  Anticancer Res       Date:  2004 Sep-Oct       Impact factor: 2.480

8.  Evidence for autocrine mitogenic stimulation by somatomedin-C/insulin-like growth factor I on an established human lung cancer cell line.

Authors:  F Minuto; P Del Monte; A Barreca; A Alama; G Cariola; G Giordano
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701

9.  Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.

Authors:  Yasuyoshi Miyata; Hideki Sakai; Tomayoshi Hayashi; Hiroshi Kanetake
Journal:  Prostate       Date:  2003-02-01       Impact factor: 4.104

10.  Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

Authors:  H Yu; M R Spitz; J Mistry; J Gu; W K Hong; X Wu
Journal:  J Natl Cancer Inst       Date:  1999-01-20       Impact factor: 13.506

View more
  5 in total

1.  Expression and clinical significance of insulin-like growth factor 1 in lung cancer tissues and perioperative circulation from patients with non-small-cell lung cancer.

Authors:  S Fu; H Tang; Y Liao; Q Xu; C Liu; Y Deng; J Wang; J Wang; X Fu
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

2.  26S proteasome and insulin-like growth factor-1 in serum of dogs suffering from malignant tumors.

Authors:  Ingrid Gerke; Franz-Josef Kaup; Stephan Neumann
Journal:  Can J Vet Res       Date:  2018-04       Impact factor: 1.310

3.  BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.

Authors:  S Elizabeth Franks; Robert A Jones; Ritesh Briah; Payton Murray; Roger A Moorehead
Journal:  BMC Res Notes       Date:  2016-03-01

Review 4.  The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer.

Authors:  Alexander W Pohlman; Hita Moudgalya; Lia Jordano; Gabriela C Lobato; David Gerard; Michael J Liptay; Christopher W Seder; Jeffrey A Borgia
Journal:  Oncotarget       Date:  2022-02-18

5.  Investigation of IGF1, IGF2BP2, and IGFBP3 variants with lymph node status and esophagogastric junction adenocarcinoma risk.

Authors:  Weifeng Tang; Shuchen Chen; Jun Liu; Chao Liu; Yafeng Wang; Mingqiang Kang
Journal:  J Cell Biochem       Date:  2018-10-18       Impact factor: 4.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.